Evidence map›Paper›PMID 40909600›Full record

ArticlebioRxiv : the preprint server for biology2025

Molecular prosthetics for CFTR designed for anion selectivity outperform amphotericin B in cultured cystic fibrosis airway epithelia.

Jonnathan P Marin-Toledo, Daniel Greenan, Nohemy Celis, Laura Haske, Agnieszka Lewandowska, Christopher K Rakowski, Shashank Shastry, Arun Maji, Kelsie J Green, Taras V Pogorelov and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jonnathan P Marin-ToledoDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID 0000-0003-0582-2794
Daniel GreenanDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID 0000-0003-4805-6436
Nohemy CelisDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID 0000-0002-3031-0857
Laura HaskeDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Agnieszka LewandowskaDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID 0000-0001-8593-0781
Christopher K RakowskiDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID 0009-0003-7680-2085
Shashank ShastryDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID 0000-0002-0721-1471
Arun MajiDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID 0000-0001-8193-3758
Kelsie J GreenDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID 0009-0003-7939-7193
Taras V PogorelovDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID 0000-0001-5851-7721
Michael J WelshDepartment of Internal Medicine, Pappajohn Biomedical Institute, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0002-1646-6206
Ian M ThornellDepartment of Internal Medicine, Pappajohn Biomedical Institute, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0001-5535-2925
Martin D BurkeDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID 0000-0001-7963-7140

Funding

Pathology CoreP01HL152960 · NHLBI · UNIVERSITY OF IOWA · PI ENGELHARDT, JOHN F · 2020 to 2024
$11.6M
Molecular Prosthetics and Lego ChemistryR35GM118185 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Martin D Burke · 2016 to 2026
$6.6M
Training Program at the Chemistry Biology InterfaceT32GM136629 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Paul Hergenrother · 2020 to 2026
$4.5M
NHLBI NIH HHS P01 HL152960NIGMS NIH HHS R35 GM118185NIGMS NIH HHS T32 GM136629
6 · The paper itself

Abstract

The ion channel-forming natural product amphotericin B (AmB) can serve as a molecular prosthetic for the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel and thereby restore host defenses in cultured cystic fibrosis (CF) airway epithelia. This is despite the fact that the permeability of AmB-based channels favors cations, and these channels lose their capacity to increase airway surface liquid (ASL) pH in CF airway epithelia at high concentrations. We hypothesize that modifying such channels to favor anion permeability would make them more CFTR-like and thus increase their potential therapeutic effects compared to AmB. Here we show that a synthetic derivative of AmB, AmB-AA, which has an added positively charged appendage and forms ion channels with an improved relative permeability to anions, outperformed AmB in increasing the ASL pH in CF airway epithelia at both low and high concentrations. Further modifications led to another AmB derivative, C2'epiAmB-AA, that also minimized cholesterol binding and thus toxicity to cultured CF airway epithelia and was an effective surrogate for CFTR in primary cultured airway epithelia from people with CF.

Identifiers

PMID40909600
PMCPMC12407901

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.